companiesandmarkets.com

Return to Report | Print

Becton, Dickinson and Co - Premium Company Profile

http://www.companiesandmarkets.com/Summary-Company-Profile/becton,-dickinson-and-co-premium-company-profile-42824.asp

Report Summary

Introduction

Becton, Dickinson and Company (BD), a medical technology company, improves drug therapy, enhances the diagnosis of infectious diseases and advances drug discovery. It manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. It serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Highlights

    BD’s business includes medical, diagnostics and biosciences segments. The medical segment produces an array of medical devices including safety engineered injection, infusion therapy devices, pre-fillable drug delivery systems, and surgical blades.

    The diagnostics segment provides products for the safe collection and transport of diagnostic specimens, and instrumentation for analysis for a range of microbiology and infectious disease testing. The biosciences segment produces research and clinical tools that facilitate the study of cells used to aid in the development of new drugs.

    BD’s historical revenues increased at a CAGR of 10% from 3,960 million to $5,835 million over the historical period 2002-2006, primarily due to sales of medical surgical systems that include sales safety-engineered products and prefilled flush syringes.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Overview 1
    Catalyst 1
    Summary 1
    Table of Contents 2
    Table of figures 3
    Tables 4
    Company Structure 5
    Company Overview and Key Facts 5
    Business Description 6
    History 7
    M&A History 10
    Atto Bioscience 10
    GeneOhm Sciences 10
    Locations and Subsidiaries 11
    Company Financials 12
    Stock Market Performance 12
    P&L 13
    Balance Sheet 16
    Cash Flow 16
    Geographic Segment Performance 17
    Products & Services 18
    Marketed Products 18
    BD vacutainer push button blood collection 19
    Ace elastic bandages 19
    Insulin syringes 19
    BD FACSCalibur system 19
    BD FACSCount system 19
    Diagnostic systems 19
    BD BACTEC system 19
    BD FACSCanto II system 20
    BD LSR II Flow Cytometer 20
    Prefillable Injection System 20
    Historical Product Sales 21
    AC Forecast Product Sales 23
    Competitors and Strategic Business Relationships 25
    Key Competitors 25
    Key Clients 26
    Shareholding Structure 27
    Strategy 28
    Company View 28
    Corporate Strategy 33
    SWOT Analysis 35
    Overview 35
    Strengths 36
    Product development 36
    Global presence 36
    Commitment to productivity improvements 36
    Weaknesses 38
    Weak performance of Phoenix 38
    Exit from blood glucose monitoring market 38
    Opportunities 39
    Acquisitions 39
    HAI market 39
    Growing incidence of diabetes 40
    Threats 41
    Lawsuits 41
    Deficit reduction act 41
    Industry consolidation 41
    Value Chain Analysis 42
    Overview 42
    Product Development 42
    Manufacturing 42
    Sales 43
    Key Employees 44
    List of Employees 44
    Key Employee Biographies 46
    Edward J Ludwig 46
    John R Considine 46
    Basil L Anderson 46
    Henry P Becton 47
    Edward F DeGraan 47
    Gary A Mecklenburg 47
    James F Orr 48
    Willard J Overlock 48
    James E Perrella 48
    Bertram L Scott 49
    Adel A.F. Mahmoud 49
    Alfred Sommer 49
    Cathy E Minehan 50
    Claire M Fraser-Liggett 50
    Marshall O Larsen 50
    Jeffrey S Sherman 51
    Financial and Operational Overview 52
    Financial and Operational Overview 52
    APPENDIX 54
    Ask the analyst 54
    Datamonitor consulting 54
    Disclaimer 54
    List of Tables
    Table 1: Becton, Dickinson and Company - Key Facts 5
    Table 2: Becton, Dickinson and Company- Locations and Subsidiaries 11
    Table 3: Becton, Dickinson and Company- Year-End Share Price and Market Capitalization, 2002-2006 ($) 12
    Table 4: Becton, Dickinson and Company- Key Events Impacting Share Price Performance 12
    Table 5: Becton, Dickinson and Company- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
    Table 6: Becton, Dickinson and Company- Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 15
    Table 7: Becton, Dickinson and Company- Balance Sheet 16
    Table 8: Becton, Dickinson and Company- Cash Flow 16
    Table 9: Becton, Dickinson and Company- Geographic Breakdown, 2002-2006 ($ Mn) 17
    Table 10: Becton, Dickinson and Company- Marketed Products 18
    Table 11: Becton, Dickinson and Company- Historical Product Sales, 2002-2006 ($ Mn) 21
    Table 12: Becton, Dickinson and Company- Forecast Sales, 2006-2010 ($ Mn) 23
    Table 13: Becton, Dickinson and Company- Key Competitors 25
    Table 14: Becton, Dickinson and Company- Key Shareholders 27
    Table 15: Becton, Dickinson and Company- SWOT Analysis Summary 35
    Table 16: Becton, Dickinson and Company- Value Chain Analysis 42
    Table 17: Becton, Dickinson and Company- Key Employees 44
    Table 18: Becton, Dickinson and Company - Financial and Operational Overview 52
    List of Figures
    Figure 1: Becton, Dickinson and Company- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14
    Figure 2: Becton, Dickinson and Company- Key Strateguc Revenues, 2002-2006 ($ Mn) 22
    Figure 3: Becton, Dickinson and Company- Key Strategic Revenues, 2006-2010 ($ Mn) 24